Mesenchymal Stem Cells: a Promising Therapeutic Tool for Acute Kidney Injury

Autor: Nehal S. Abouhashem, Rasha E. Hassan, Somia H. Abd-Allah, Gilane M. Sabry, Rehab E. Selim, Wagdy K. B. Khalil, Hanaa H. Ahmed
Rok vydání: 2019
Předmět:
Male
0106 biological sciences
medicine.medical_specialty
medicine.medical_treatment
Urology
Renal function
Antineoplastic Agents
Bioengineering
Mesenchymal Stem Cell Transplantation
urologic and male genital diseases
01 natural sciences
Applied Microbiology and Biotechnology
Biochemistry
Cell therapy
chemistry.chemical_compound
010608 biotechnology
medicine
Animals
Renal replacement therapy
Rats
Wistar
Molecular Biology
Kidney
Creatinine
biology
010405 organic chemistry
business.industry
Acute kidney injury
Mesenchymal Stem Cells
General Medicine
Acute Kidney Injury
medicine.disease
female genital diseases and pregnancy complications
Rats
0104 chemical sciences
Vascular endothelial growth factor
medicine.anatomical_structure
Adipose Tissue
chemistry
Cystatin C
biology.protein
Cisplatin
business
Biotechnology
Zdroj: Applied Biochemistry and Biotechnology. 189:284-304
ISSN: 1559-0291
0273-2289
DOI: 10.1007/s12010-019-02995-2
Popis: Acute kidney injury (AKI) is a rapid loss of renal function. It has high mortality rates. Still, renal replacement therapy is considered the best solution for recovering AKI. This opens a line of thought to develop an alternative therapy for it without complications. Mesenchymal stem cells are considered a new therapy for treating kidney diseases. The aim of this work was to address the anti-apoptotic, antioxidative, and pro-angiogenic effects of adipose tissue-derived MSCs (AD-MSCs) and bone marrow-MSCs (BM-MSCs) for treating AKI. Adult male Wistar rats were assigned into nine groups (n = 10): (1) the control group; (2) the AKI group, receiving cisplatin; (3) the AKI group treated with AD-MSCs (1 × 106); (4) the AKI group treated with AD-MSCs (2 × 106); (5) the AKI group treated with AD-MSCs (4 × 106); (6) the AKI group treated with losartan; (7) the AKI group treated with BM-MSCs (1 × 106); (8) the AKI group treated with BM-MSCs (2 × 106); and (9) the AKI group treated with BM-MSCs (4 × 106). The results showed a significant rise in creatinine, urea, and cystatin C (cys C) levels and upregulation of p38 mRNA, whereas a significant decline in NAD(P)H quinone oxidoreductase 1 (NQO-1) protein and downregulation of B-cell lymphoma-2 (Bcl-2) mRNA and vascular endothelial growth factor (VEGF) mRNA were recorded in AKI. MSCs could improve renal functions manifested by decreased urea, creatinine, and cys C levels; downregulation of p38; and upregulation of Bcl-2 and VEGF. Moreover, MSC therapy could induce NQO-1 in the treated rats relative to the untreated rats. So, cell-based therapy can reduce AKI through the antioxidative, anti-apoptotic, and pro-angiogenic properties of MSCs. Therefore, the findings received in this attempt create a fertile base for the setup of cell therapy in patients with AKI.
Databáze: OpenAIRE
Externí odkaz: